<Suppliers Price>

CGP 3466B maleate

Names

[ CAS No. ]:
200189-97-5

[ Name ]:
CGP 3466B maleate

[Synonym ]:
JHW 007 hydrochloride
Omigapil maleate
Dibenzo(b,f)oxepin-10-ylmethyl-methyl-prop-2-ynyl-amine maleate
TCH-346
CGP 3466B
UNII-3Q69BFZ4OP
N-(Dibenz(b,f)oxepin-10-ylmethyl)-N-methyl-N-(2-propynyl)amine monomaleic acid salt

Biological Activity

[Description]:

Omigapil maleate (CGP3446B maleate) is an orally bioavailable apoptosis inhibitor. Omigapil maleate can be used for the research of congenital muscular dystrophy (CMD)[1]. Omigapil maleate, a GAPDH nitrosylation inhibitor, abrogates Aβ1-42-induced tau acetylation, memory impairment, and locomotor dysfunction in mice, suggesting that Omigapil maleate has the potential for the research of Alzheimer's disease[2].

[Related Catalog]:

Signaling Pathways >> Apoptosis >> Apoptosis
Research Areas >> Metabolic Disease
Research Areas >> Neurological Disease

[Target]

Apoptosis[2]


[In Vivo]

Treatment of mice with Omigapil (0.1 mg/kg) results in improved muscle regeneration and increased force[1]. Animal Model: 12-week-old dyW/ mag mice[1] Dosage: 0.1 mg/kg Administration: For the first week of drug treatment, administered once daily by intraperitoneal injection. After weaning (3 weeks of age), applied once daily by oral gavage. Result: Reduced the muscle fibre loss. Many of the functional parameters were significantly improved by omigapil.

[References]

[1]. Sarina Meinen, et al. Apoptosis inhibitors and mini-agrin have additive benefits in congenital muscular dystrophy mice. EMBO Mol Med. 2011 Aug;3(8):465-79.

[2]. Tanusree Sen, et al. Nitrosylation of GAPDH augments pathological tau acetylation upon exposure to amyloid-β. Sci Signal. 2018 Mar 20;11(522):eaao6765.

Chemical & Physical Properties

[ Molecular Formula ]:
C23H21NO5

[ Molecular Weight ]:
391.41700

[ Exact Mass ]:
391.14200

[ PSA ]:
87.07000

[ LogP ]:
3.60970

Related Compounds